Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Gastric Neuroendocrine CarcinomaPancreatic Neuroendocrine CarcinomaIntestinal Neuroendocrine Carcinoma
- Interventions
- Drug: CarboplatinDrug: CapecitabineOther: Laboratory Biomarker AnalysisDrug: CisplatinDrug: TemozolomideDrug: Etoposide
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 67
- Registration Number
- NCT02595424
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3bFollicular Lymphoma, Grade 3b
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02592876
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-10-10
- Target Recruit Count
- 39
- Registration Number
- NCT02583893
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
- Conditions
- Germ Cell Tumor
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 500
- Registration Number
- NCT02582697
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 60
- Registration Number
- NCT02574728
- Locations
- 🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-NegativeStage II Angioimmunoblastic T-cell LymphomaStage IV Enteropathy-Associated T-Cell LymphomaStage III Angioimmunoblastic T-cell LymphomaStage IV Angioimmunoblastic T-cell LymphomaStage II Enteropathy-Associated T-Cell LymphomaHepatosplenic T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedStage III Enteropathy-Associated T-Cell Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideOther: Laboratory Biomarker AnalysisDrug: LenalidomideProcedure: Peripheral Blood Stem Cell TransplantationDrug: PrednisoneDrug: Vincristine Sulfate
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 54
- Registration Number
- NCT02561273
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02549261
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
- Conditions
- Extranodal NK-T-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02544425
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Recurrent T Lymphoblastic Leukemia/LymphomaB Lymphoblastic LymphomaRecurrent B Lymphoblastic LymphomaRefractory T Lymphoblastic LymphomaT Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRefractory B Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Imatinib MesylateOther: Laboratory Biomarker AnalysisDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02538926
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.